Involvement of adenosine A2A receptors in depression and anxiety

International Review of Neurobiology

Volumn 119, Issue , 2014, Pages 373-393

  Yamada, Koji ^a   Kobayashi, Minoru ^a   Kanda, Tomoyuki ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

Antagonist; Anxiety; Behavior; Depression; Istradefylline; Mental illness; Rodents

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 6 N [2 (3,5 DIMETHOXYPHENYL) 2 (2 METHYLPHENYL)ETHYL]ADENOSINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; BRAIN DERIVED NEUROTROPHIC FACTOR; CAFFEINE; DOPAMINE; DOPAMINE 2 RECEPTOR; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; HALOPERIDOL; ISTRADEFYLLINE; MONOAMINERGIC NEUROTRANSMITTER; NEUROTRANSMITTER; SEROTONIN; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; UNCLASSIFIED DRUG; ADENOSINE A2 RECEPTOR ANTAGONIST;

ANTIDEPRESSANT ACTIVITY; ANXIETY; ANXIETY DISORDER; ANXIETY LIKE BEHAVIOR; ARTICLE; COFFEE; DEPRESSION; DISEASE ASSOCIATION; DISEASE MODEL; DRUG BINDING SITE; DRUG MECHANISM; EXPERIMENTAL ANIMAL; GENE DELETION; GENETIC MANIPULATION; GENETIC POLYMORPHISM; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; KNOCKOUT MOUSE; MONOAMINERGIC SYSTEM; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR BLOCKING; RISK BENEFIT ANALYSIS; TRANQUILIZING ACTIVITY; ANIMAL; METABOLISM;

ADENOSINE A2 RECEPTOR ANTAGONISTS; ANIMALS; ANXIETY; CAFFEINE; DEPRESSION; HUMANS; RECEPTOR, ADENOSINE A2A;

EID: 84906739089     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-801022-8.00015-5     Document Type: Chapter

References (106)

1. Alsene K., Deckert J., Sand P., de Wit H. Association between A2a receptor gene polymorphisms and caffeine-Induced anxiety. Neuropsychopharmacology 2003, 28(9):1694-1702.
2. Baldwin H.A., File S.E. Caffeine-Induced anxiogenesis: The role of adenosine, benzodiazepine and noradrenergic receptors. Pharmacology, Biochemistry, and Behavior 1989, 32(1):181-186.
3. Barone P. Treatment of depressive symptoms in Parkinson's disease. European Journal of Neurology 2011, 18(Suppl 1):11-15.
4. Bhattacharya S.K., Satyan K.S., Chakrabarti A. Anxiogenic action of caffeine: An experimental study in rats. Journal of Psychopharmacology 1997, 11(3):219-224.
5. Boulenger J.P., Uhde T.W., Wolff E.A., Post R.M. Increased sensitivity to caffeine in patients with panic disorders. Preliminary evidence. Archives of General Psychiatry 1984, 41(11):1067-1071.
6. Bruce M.S. The anxiogenic effects of caffeine. Postgraduate Medical Journal 1990, 66(Suppl 2):S18-S24.
7. Charney D.S., Heninger G.R., Jatlow P.I. Increased anxiogenic effects of caffeine in panic disorders. Archives of General Psychiatry 1985, 42(3):233-243.
8. Chau A., Rose J.C., Koos B.J. Adenosine modulates corticotropin and cortisol release during hypoxia in fetal sheep. American Journal of Obstetrics & Gynecology 1999, 180(5):1272-1277.
9. Chen B., Dowlatshahi D., MacQueen G.M., Wang J.F., Young L.T. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biological Psychiatry 2001, 50(4):260-265.
10. 2A adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. The Journal of Neuroscience 1999, 19(21):9192-9200.
11. Chen J., Rinaldo L., Lim S.J., Young H., Messing R.O., Choi D.S. The type 1 equilibrative nucleoside transporter regulates anxiety-like behavior in mice. Genes, Brain, and Behavior 2007, 6(8):776-783.
12. 2A receptors in the modulation of LTP in the rat hippocampus upon ageing. European Journal of Neuroscience 2011, 34(1):12-21.
13. 2A adenosine receptors. Physiology & Behavior 2013, 109:1-7.
14. 2A receptors upon sub-chronic restraint stress. Neuroscience 2006, 141(4):1775-1781.
15. 2A receptor impairs long term potentiation in the accumbens nucleus without altering basal synaptic transmission. Neuroscience 2001, 107(3):455-464.
16. D'Aquila P.S., Collu M., Pani L., Gessa G.L., Serra G. Antidepressant-like effect of selective dopamine D1 receptor agonists in the behavioural despair animal model of depression. European Journal of Pharmacology 1994, 262:107-111.
17. Deckert J., Nothen M.M., Franke P., Delmo C., Fritze J., Knapp M., et al. Systematic mutation screening and association study of the A1 and A2a adenosine receptor genes in panic disorder suggest a contribution of the A2a gene to the development of disease. Molecular Psychiatry 1998, 3(1):81-85.
18. Deussing J.M. Animal models of depression. Drug Discovery Today: Disease Models 2006, 3(4):375-383.
19. 2A receptor facilitates brain-derived neurotrophic factor modulation of synaptic transmission in hippocampal slices. The Journal of Neuroscience 2004, 24(12):2905-2913.
20. Dixon A.K., Gubitz A.K., Sirinathsinghji D.J., Richardson P.J., Freeman T.C. Tissue distribution of adenosine receptor mRNAs in the rat. British Journal of Pharmacology 1996, 118(6):1461-1468.
21. Duman C.H. Models of depression. Vitamins & Hormones 2010, 82:1-21.
22. Duster R., Prickaerts J., Blokland A. Purinergic signaling and hippocampal long-term potentiation. Current Neuropharmacology 2014, 12(1):37-43.
23. 2A receptors and depression. Neurology 2003, 61(11 Suppl 6):S82-S87.
24. 2A receptor knockout mice. British Journal of Pharmacology 2001, 134(1):68-77.
25. 2A adenosine receptor antagonists. Psychopharmacology 2000, 148(2):153-163.
26. 2A receptor antagonism reverses the effects of dopamine receptor antagonism on instrumental output and effort-related choice in the rat: Implications for studies of psychomotor slowing. Psychopharmacology 2007, 191(3):579-586.
27. Ferré S. An update on the mechanisms of the psychostimulant effects of caffeine. Journal of Neurochemistry 2008, 105(4):1067-1079.
28. Flores B.H., Kenna H., Keller J., Solvason H.B., Schatzberg A.F. Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology 2006, 31(3):628-636.
29. 1 receptors modulate anxiety in CD1 mice. Psychopharmacology 1998, 136(4):311-319.
30. 2A agonist CGS 21680 affect effort-Related choice behavior in rats. Psychopharmacology 2008, 199(4):515-526.
31. Gillman P.K. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. British Journal of Pharmacology 2007, 151(6):737-748.
32. Gimenez-Llort L., Fernandez-Teruel A., Escorihuela R.M., Fredholm B.B., Tobena A., Pekny M., et al. Mice lacking the adenosine A1 receptor are anxious and aggressive, but are normal learners with reduced muscle strength and survival rate. European Journal of Neuroscience 2002, 16(3):547-550.
33. Greden J.F., Fontaine P., Lubetsky M., Chamberlin K. Anxiety and depression associated with caffeinism among psychiatric inpatients. The American Journal of Psychiatry 1978, 135(8):963-966.
34. Green P.J., Suls J. The effects of caffeine on ambulatory blood pressure, heart rate, and mood in coffee drinkers. Journal of Behavioral Medicine 1996, 19(2):111-128.
35. 2-receptor antagonist, CGS 15943A, and an A1-selective antagonist, DPCPX. Psychopharmacology 1991, 103(4):541-544.
36. Haenisch B., Bonisch H. Depression and antidepressants: Insights from knockout of dopamine, serotonin or noradrenaline re-uptake transporters. Pharmacology & Therapeutics 2011, 129:352-368.
37. Hamilton S.P., Slager S.L., De Leon A.B., Heiman G.A., Klein D.F., Hodge S.E., et al. Evidence for genetic linkage between a polymorphism in the adenosine 2A receptor and panic disorder. Neuropsychopharmacology 2004, 29(3):558-565.
38. Haskell C.F., Kennedy D.O., Wesnes K.A., Scholey A.B. Cognitive and mood improvements of caffeine in habitual consumers and habitual non-consumers of caffeine. Psychopharmacology 2005, 179(4):813-825.
39. Huang Q.J., Minor T.R. Adenosine mediates reserpine-induced behavioral depression in rats. Brain, Behavior, and Immunity 2000, 14:101.
40. Imaizumi M., Miyazaki S., Onodera K. Effects of xanthine derivatives in a light/dark test in mice and the contribution of adenosine receptors. Methods and Findings in Experimental and Clinical Pharmacology 1994, 16(9):639-644.
41. Jahn H., Schick M., Kiefer F., Kellner M., Yassouridis A., Wiedemann K. Metyrapone as additive treatment in major depression: A double-blind and placebo-controlled trial. Archives of General Psychiatry 2004, 61(12):1235-1244.
42. Jain N., Kemp N., Adeyemo O., Buchanan P., Stone T.W. Anxiolytic activity of adenosine receptor activation in mice. British Journal of Pharmacology 1995, 116(3):2127-2133.
43. 2A receptor gene disruption provokes marked changes in melanocortin content and pro-opiomelanocortin gene expression. Journal of Neuroendocrinology 2003, 15(12):1171-1177.
44. 1 receptor. Proceedings of the National Academy of Sciences 2001, 98(16):9407-9412.
45. Kaster M.P., Budni J., Santos A.R., Rodrigues A.L. Pharmacological evidence for the involvement of the opioid system in the antidepressant-like effect of adenosine in the mouse forced swimming test. European Journal of Pharmacology 2007, 576(1-3):91-98.
46. 2A receptors. Neuroscience Letters 2004, 355(1-2):21-24.
47. Kaster M.P., Rosa A.O., Santos A.R., Rodrigues A.L. Involvement of nitric oxide-cGMP pathway in the antidepressant-like effects of adenosine in the forced swimming test. The International Journal of Neuropsychopharmacology 2005, 8(4):601-606.
48. 1A receptors in the antidepressant-like effect of adenosine in the mouse forced swimming test. Brain Research Bulletin 2005, 67(1-2):53-61.
49. Kawachi I., Willett W.C., Colditz G.A., Stampfer M.J., Speizer F.E. A prospective study of coffee drinking and suicide in women. Archives of Internal Medicine 1996, 156(5):521-525.
50. Kendler K.S., Myers J.O., Gardner C. Caffeine intake, toxicity and dependence and lifetime risk for psychiatric and substance use disorders: An epidemiologic and co-twin control analysis. Psychological Medicine 2006, 36(12):1717-1725.
51. Klatsky A.L., Armstrong M.A., Friedman G.D. Coffee, tea, and mortality. Annals of Epidemiology 1993, 3(4):375-381.
52. Kobayashi, M., Kase, J., Yamada, K., Mori, A., Jenner, P., & Kanda, T. (2014). Anxiolytic-like activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002) in the rat elevated plus maze. Submitted.
53. 2A receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats. European Journal of Pharmacology 2000, 408:249-255.
54. Koran L.M., Aboujaoude E., Gamel N.N. Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder. Journal of Clinical Psychiatry 2009, 70(11):1530-1535.
55. Kulkarni S.K., Mehta A.K. Purine nucleoside-mediated immobility in mice: Reversal by antidepressants. Psychopharmacology 1985, 85(4):460-463.
56. Kulkarni S.K., Singh K., Bishnoi M. Involvement of adenosinergic receptors in anxiety related behaviours. Indian Journal of Experimental Biology 2007, 45(5):439-443.
57. 2a adenosine receptor genetic polymorphism in panic disorder. Neuroscience Letters 2005, 378(2):98-101.
58. Lang U.E., Lang F., Richter K., Vallon V., Lipp H.P., Schnermann J., et al. Emotional instability but intact spatial cognition in adenosine receptor 1 knock out mice. Behavioural Brain Research 2003, 145(1-2):179-188.
59. Ledent C., Vaugeois J.M., Schiffmann S.N., Pedrazzini T., El Yacoubi M., Vanderhaeghen J.J., et al. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature 1997, 388(6643):674-678.
60. Lieberman H.R., Tharion W.J., Shukitt-Hale B., Speckman K.L., Tulley R. Effects of caffeine, sleep loss, and stress on cognitive performance and mood during U.S. Navy SEAL training. Sea-Air-Land. Psychopharmacology 2002, 164(3):250-261.
61. Lieberman H.R., Wurtman R.J., Emde G.G., Coviella I.L. The effects of caffeine and aspirin on mood and performance. Journal of Clinical Psychopharmacology 1987, 7(5):315-320.
62. Loke W.H. Effects of caffeine on mood and memory. Physiology & Behavior 1988, 44(3):367-372.
63. Lopes L.V., Sebastiao A.M., Ribeiro J.A. Adenosine and related drugs in brain diseases: Present and future in clinical trials. Current Topics in Medicinal Chemistry 2011, 11(8):1087-1101.
64. 1 receptors. Journal of Pharmacological Sciences 2004, 96(1):42-52.
65. Martinowich K., Manji H., Lu B. New insights into BDNF function in depression and anxiety. Nature Neuroscience 2007, 10(9):1089-1093.
66. 2A receptors regulate exertion of effort by acting on the ventral striatopallidal pathway. The Journal of Neuroscience 2008, 28(36):9037-9046.
67. Minor T.R., Chang W.C., Winslow J.L. Stress and adenosine: I Effect of methylxanthine and amphetamine stimulants on learned helplessness in rats. Behavioral Neuroscience 1994, 108(2):254-264.
68. Minor T.R., Winslow J.L., Chang W.C. Stress and adenosine: II. Adenosine analogs mimic the effect of inescapable shock on shuttle-escape performance in rats. Behavioral Neuroscience 1994, 108(2):265-276.
69. 2A receptors: An overview. Brain Research. Brain Research Reviews 1999, 31(1):65-82.
70. 2A antagonists. Neurology 2003, 61(11 Suppl 6):S44-S48.
71. Okada M., Nutt D.J., Murakami T., Zhu G., Kamata A., Kawata Y., et al. Adenosine receptor subtypes modulate two major functional pathways for hippocampal serotonin release. The Journal of Neuroscience 2001, 21(2):628-640.
72. Olesen J., Gustavsson A., Svensson M., Wittchen H.U., Jonsson B., CDBE2010 study group, et al. The economic cost of brain disorders in Europe. European Journal of Neurology 2012, 19(1):155-162.
73. 2A receptors. Trends in Pharmacological Sciences 1996, 17(10):364-372.
74. Pariante C.M., Lightman S.L. The HPA axis in major depression: Classical theories and new developments. Trends in Neurosciences 2008, 31(9):464-468.
75. Pariante C.M., Miller A.H. Glucocorticoid receptors in major depression: Relevance to pathophysiology and treatment. Biological Psychiatry 2001, 49(5):391-404.
76. Porsolt R.D., Le Pichon M., Jalfre M. Depression: A new animal model sensitive to antidepressant treatments. Nature 1977, 266:730-732.
77. 1 receptors modulate the anxiolytic-like effect of ethanol in the elevated plus-maze in mice. European Journal of Pharmacology 2004, 499(1-2):147-154.
78. Prediger R.D., da Silva G.E., Batista L.C., Bittencourt A.L., Takahashi R.N. Activation of adenosine A1 receptors reduces anxiety-like behavior during acute ethanol withdrawal (hangover) in mice. Neuropsychopharmacology 2006, 31(10):2210-2220.
79. 2A receptors are essential for long-term potentiation of NMDA-EPSCs at hippocampal mossy fiber synapses. Neuron 2008, 57(1):121-134.
80. Reijnders J.S., Ehrt U., Weber W.E., Aarsland D., Leentjens A.F. A systematic review of prevalence studies of depression in Parkinson's disease. Movement Disorders 2008, 23(2):183-189.
81. Reul J.M., Labeur M.S., Grigoriadis D.E., De Souza E.B., Holsboer F. Hypothalamic-pituitary-adrenocortical axis changes in the rat after long-term treatment with the reversible monoamine oxidase-A inhibitor moclobemide. Neuroendocrinology 1994, 60(5):509-519.
82. Reul J.M., Stec I., Soder M., Holsboer F. Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system. Endocrinology 1993, 133(1):312-320.
83. Rihs M., Muller C., Baumann P. Caffeine consumption in hospitalized psychiatric patients. European Archives of Psychiatry and Clinical Neuroscience 1996, 246(2):83-92.
84. 2A receptors in the rat central nervous system. Journal of Comparative Neurology 1998, 401(2):163-186.
85. 2A receptor antagonist istradefylline Naunyn-Schmiedeberg's. Archives of Pharmacology 2013, 386:963-972.
86. Salamone J.D., Correa M., Nunes E.J., Randall P.A., Pardo M. The behavioral pharmacology of effort-related choice behavior: Dopamine, adenosine and beyond. Journal of the Experimental Analysis of Behavior 2012, 97(1):125-146.
87. 2 antagonism. Behavioural Brain Research 2009, 201(1):216-222.
88. Scaccianoce S., Navarra D., Di Sciullo A., Angelucci L., Endroczi E. Adenosine and pituitary-adrenocortical axis activity in the rat. Neuroendocrinology 1989, 50(4):464-468.
89. 2A receptors and basal ganglia physiology. Progress in Neurobiology 2007, 83(5):277-292.
90. Sen S., Nesse R.M., Stoltenberg S.F., Li S., Gleiberman L., Chakravarti A., et al. A BDNF coding variant is associated with the NEO personality inventory domain neuroticism, a risk factor for depression. Neuropsychopharmacology 2003, 28(2):397-401.
91. Sherman A.D., Sacquitne J.L., Petty F. Specificity of the learned helplessness model of depression. Pharmacology, Biochemistry, and Behavior 1982, 16(3):449-454.
92. Shiozaki S., Ichikawa S., Nakamura J., Kitamura S., Yamada K., Kuwana Y. Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology 1999, 147:90-95.
93. Smith A.P. Caffeine, cognitive failures and health in a non-working community sample. Human Psychopharmacology 2009, 24(1):29-34.
94. Stern K.N., Chait L.D., Johanson C.E. Reinforcing and subjective effects of caffeine in normal human volunteers. Psychopharmacology 1989, 98(1):81-88.
95. 2A receptors. Progress in Neurobiology 1999, 59(4):355-396.
96. Tanskanen A., Tuomilehto J., Viinamaki H., Vartiainen E., Lehtonen J., Puska P. Heavy coffee drinking and the risk of suicide. European Journal of Epidemiology 2000, 16(9):789-791.
97. 2A receptors are required for normal BDNF levels and BDNF-induced potentiation of synaptic transmission in the mouse hippocampus. Journal of Neurochemistry 2008, 104(1):279-286.
98. 2a receptor antagonist 3,7-dimethyl-propargylxanthine on anxiety-like and depression-like behavior and alcohol consumption in Wistar Rats. Alcoholism, Clinical and Experimental Research 2007, 31(8):1302-1307.
99. 2A receptors in forebrain. Biological Psychiatry 2014, 75:855-863.
100. Wittchen H.U., Jacobi F., Rehm J., Gustavsson A., Svensson M., Jonsson B., et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. European Neuropsychopharmacology 2011, 21(9):655-679.
101. Woodson J.C., Minor T.R., Job R.F. Inhibition of adenosine deaminase by erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) mimics the effect of inescapable shock on escape learning in rats. Behavioral Neuroscience 1998, 112(2):399-409.
102. Yamada K., Hattori E., Shimizu M., Sugaya A., Shibuya H., Yoshikawa T. Association studies of the cholecystokinin B receptor and A2a adenosine receptor genes in panic disorder. Journal of Neural Transmission 2001, 108(7):837-848.
103. 2A receptor antagonist, istradefylline (KW-6002), in the forced swim test and the tail suspension test in rodents. Pharmacology, Biochemistry, and Behavior 2013, 114-115:23-30.
104. 2A receptor antagonist, istradefylline (KW-6002) on learned helplessness in rats. Psychopharmacology 2014, 231:2839-2849.
105. Yamato T., Yamasaki S., Misumi Y., Kino M., Obata T., Aomine M. Modulation of the stress response by coffee: An in vivo microdialysis study of hippocampal serotonin and dopamine levels in rat. Neuroscience Letters 2002, 332(2):87-90.
106. Zangrossi H., Leite J.R., Graeff F.G. Anxiolytic effect of carbamazepine in the elevated plus-maze: Possible role of adenosine. Psychopharmacology 1992, 106(1):85-89.